Hikal Ltd Stock Falls to 52-Week Low of Rs.217 Amidst Continued Weakness

Stock Performance and Market Context

On the day, Hikal Ltd’s stock touched an intraday low of Rs.217, representing a 2.8% decline and underperforming the Pharmaceuticals & Biotechnology sector by 0.48%. This new low contrasts starkly with the stock’s 52-week high of Rs.456.6, reflecting a substantial depreciation of over 52% from its peak within the last year.

The broader market environment also showed weakness, with the Nifty closing at 25,876.85, down 263.9 points or 1.01%. The index remains 1.92% below its 52-week high of 26,373.20. Notably, the Nifty is trading below its 50-day moving average, although the 50DMA remains above the 200DMA, indicating mixed technical signals. Large-cap segments, including the Nifty Next 50, dragged the market down by 2.11%, reflecting widespread selling pressure.

Hikal’s share price is trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — underscoring a persistent downtrend and lack of short- to long-term price support.

Financial and Operational Metrics

Over the past year, Hikal Ltd’s stock has delivered a negative return of 43.20%, significantly underperforming the Sensex, which posted a positive 7.72% return over the same period. This underperformance is mirrored in the company’s financial results and operational metrics.

The company’s operating profits have declined at a compounded annual growth rate (CAGR) of -16.24% over the last five years, indicating sustained pressure on core earnings. The latest quarterly results, declared in September 2025, were notably weak, with earnings per share (EPS) falling by 320.54%. The company reported a net loss (PAT) of Rs.34.90 crores for the quarter, a steep decline compared to the previous four-quarter average.

Return on Capital Employed (ROCE) for the half-year stood at a low 4.44%, while the operating profit to interest coverage ratio dropped to 0.48 times, signalling limited capacity to cover interest expenses from operating earnings. The average return on equity (ROE) remains modest at 8.00%, reflecting subdued profitability relative to shareholders’ funds.

Debt and Valuation Considerations

Hikal Ltd’s financial leverage remains a concern, with a Debt to EBITDA ratio of 2.51 times, indicating a relatively high level of debt compared to earnings before interest, taxes, depreciation, and amortisation. This ratio suggests limited flexibility in servicing debt obligations, especially given the company’s reduced operating profits and interest coverage.

Despite these challenges, the stock’s valuation metrics present some counterpoints. The company’s ROCE of 4.1% is accompanied by an attractive Enterprise Value to Capital Employed ratio of 1.8, suggesting that the stock is trading at a discount relative to its capital base. This valuation is lower than the average historical valuations of its peers within the Pharmaceuticals & Biotechnology sector.

However, the company’s profitability has deteriorated sharply, with profits falling by 86.2% over the past year, reinforcing the downward pressure on the stock price.

Shareholding and Market Grade

Promoters remain the majority shareholders of Hikal Ltd, maintaining significant control over the company’s strategic direction. The stock’s Mojo Score currently stands at 12.0, with a Mojo Grade of Strong Sell as of 14 Nov 2025, an upgrade from the previous Sell rating. The Market Cap Grade is rated at 3, reflecting the company’s relatively modest market capitalisation within its sector.

These grades reflect the company’s weak long-term fundamental strength and recent financial performance, which have contributed to the stock’s sustained decline and new 52-week low.

Comparative Performance and Sector Trends

Hikal Ltd’s underperformance is evident not only against the Sensex but also relative to the broader BSE500 index, where it has lagged over the last three years, one year, and three months. This trend highlights persistent challenges in maintaining competitive growth and profitability within the Pharmaceuticals & Biotechnology sector.

The sector itself has experienced volatility, but Hikal’s decline has been more pronounced, reflecting company-specific factors that have weighed on investor sentiment and valuation.

While the stock’s current price level at Rs.217 represents a significant discount to its 52-week high, it also underscores the market’s cautious stance given the company’s recent financial trajectory and credit metrics.

Summary of Key Metrics

To summarise, Hikal Ltd’s key financial and market indicators as of early January 2026 are:

• 52-week low price: Rs.217


• 52-week high price: Rs.456.6


• One-year stock return: -43.20%


• Sensex one-year return: +7.72%


• Operating profit CAGR (5 years): -16.24%


• Debt to EBITDA ratio: 2.51 times


• Return on Equity (average): 8.00%


• EPS decline (latest quarter): -320.54%


• Net loss (PAT) latest quarter: Rs.34.90 crores


• ROCE (half-year): 4.44%


• Operating profit to interest coverage (quarterly): 0.48 times


• Mojo Score: 12.0 (Strong Sell)


• Market Cap Grade: 3

These figures collectively illustrate the pressures facing Hikal Ltd, reflected in its share price reaching a new 52-week low.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →